In-Vitro Evidences for the Formulation, Development, and Evaluation of Budesonide Oral Nano-sponges

Abstract

Idiopathic inflammatory bowel disease is quite common, with ulcerative colitis and Crohn's disease being the most common forms. Due to its high receptor affinity and quick diversion, the anti-inflammatory effects of the glucocorticoid budesonide are limited, but it is nevertheless useful in some situations. A unique BUD nano-sponges was developed by employing quasi-solvent diffusion and Eudragit S-100 as the polymer to address the problem of low efficacy and accessibility.

Material and Methods: Drug release profile and percentage of drug entrapment in BUD Nano sponges were also measured and analyzed. Clinical activity score, colon/body weight ratio, and macroscopic ulceration activity were among the criteria used in an in vivo investigation of the formulation in male Wistar rats. Finally, histological investigation was done on colon tissue samples.

Results: When compared to other BUD formulations on the market, this one performed exceptionally well, suggesting that the designed nanosponges are highly effective. The Wistar rats' clinical activity score was reduced when treated with the formed nanosponges. When compared to the placebo group, those who took this supplement saw a dramatic decrease in their colon weight ratio. Nanosponge colon histology revealed healthy colon anatomy and architecture.

Conclusion: The findings of this study have substantiated the efficacy of BUD nano-sponges as innovative carriers in the treatment of inflammatory bowel disease